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Recently, the loss of CDH13 (T-cadherin, H-cadherin) gene expression accompanied by CDH13 promoter methylation was identified
in colon cancers. We examined CDH13 methylation in oesophageal and gastric carcinomas. Five of 37 oesophageal cancers (14%)
and 23 of 66 gastric cancers (35%) demonstrated abnormal methylation of the CDH13 promoter. Abnormal methylation was
frequently found in gastric cancers of patients at all clinical stages just as in E-cadherin, another of the cadherin family, suggesting that
these cancers could be methylated at an early stage. These results suggested that CDH13 might play a variety of roles depending on
the tissue type.
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Advances in molecular genetics have established that several
genetic changes, such as the activation of the K-ras oncogene and
inactivation of the p53 tumour suppressor gene, are involved in the
pathogenesis of colorectal and other cancers (Bos et al, 1987;
Vogelstein et al, 1988; Baker et al, 1989). Recently, a growing
number of cancer genes are being recognised that harbour
methylation in normally unmethylated promoter CpG islands
(Jones and Laird, 1999; Baylin and Herman, 2000). This epigenetic
change results in no expression of tumour suppressor gene and
plays a key role in an epigenetically mediated loss-of-gene function
that is as critical for tumorigenesis as mutations in coding regions.
In fact, it has been confirmed that hypermethylation of a normally
unmethylated CpG island in the promoter region of p16 correlates
with its loss of transcription in various cancers (Gonzalez-Zulueta
et al, 1995; Merlo et al, 1995; Ueki et al, 2000). On the other hand,
70–80% of colorectal cancers with microsatellite instability show
aberrant promoter hypermethylation and lack expression of
hMLH1 (Herman et al, 1998).
Recently, the loss of expression of CDH13 (T-cadherin, H-
cadherin) accompanied by CDH13 promoter methylation was
reported in colon cancers (Toyooka et al, 2002). CDH13 encodes a
protein belonging to the cadherin family of cell surface glycopro-
teins responsible for selective cell recognition and adhesion
(Takeichi, 1991). Ubiquitous methylation of CDH13 in colorectal
cancers indicated that it occurs at an early stage in the multistage
process of oncogenesis. In this report, all colon cancer cell lines
that lacked CDH13 gene expression demonstrated methylation of
CpG sites within the putative CDH13 promoter. Moreover, CDH13
methylation was detected in 17 of 35 primary colon cancers,
suggesting that CDH13 is a common target for methylation and
epigenetic gene silencing in colon cancer and qualifies as a
potential colon cancer suppressor gene.
These results prompted us to examine the CDH13 status of
the whole range of digestive tract cancers. It might be possible
that CDH13 was also inactivated by methylation in other
digestive tract cancers and is associated with the tumorigenic
pathway. In this study, we first examined the methylation
status and gene expression of CDH13 in digestive tract cancer
cell lines using methylation-specific PCR (MSP) and reverse
transcription–PCR (RT–PCR), respectively. We then examined
CDH13 methylation in oesophageal and gastric carcinomas. The
results obtained were then compared to the clinicopathological
features.
MATERIALS AND METHODS
Sample collection and DNA preparation
Three colorectal cancer cell lines (SW1083, SW1222, and SW1417),
one gastric cancer cell line (MKN1), and one oesophageal
squamous cancer cell line (TE1) were kindly provided by the
Memorial Sloan-Kettering Cancer Center (New York, NY, USA) or
purchased from the American Type Culture Collection (Manassas,
VA, USA). Two gastric (NUGC3 and NUGC4) and two oesophageal
squamous cancer cell lines (NUEC1 and NUEC2) were established
in our laboratory. Primary tumours and corresponding normal
tissues were obtained at the Nagoya University Hospital from 37
oesophageal squamous cell cancer and 66 gastric cancer patients
who had been diagnosed histologically. These samples were
obtained during surgery. All cancer specimens contained more
than 70% neoplastic cells. This was confirmed using paraffin-
embedded tissues stained by haematoxylin and eosin. Oral or
written informed consent, as indicated by the institutional review
board, was obtained from all patients. All tissues were quickly
frozen in liquid nitrogen and stored at  801C until analysis. Cell
line and tumour DNA were prepared as described previously (Hibi
et al, 1998).
Bisulphite modification and MSP
DNA from tumour and normal tissue specimens was subjected to
bisulphite treatment as described previously (Hibi et al, 2001). The
modified DNA was used as a template for MSP. Primer sequences
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sof CDH13 for amplification were described previously (Sato et al,
1998). The primers for the unmethylated reaction were:
CDH13UMS (sense), 50-TTGTGGGGTTGTTTTTTGT, and
CDH13UMAS (antisense), 50-AACTTTTCATTCATACACACA,
which amplify a 242bp product. The primers for the methylated
reaction were: CDH13MS (sense), 50-TCGCGGGGTTCGTTTTT
CGC, and CDH13MAS (antisense), 50-GACGTTTTCATTCATA
CACGCG, which amplify a 243bp product. The PCR amplification
of modified DNA samples consisted of one cycle of 951C for 5min,
33 cycles of 951C for 30s, 601C for 1min, and 721C for 1min for
the unmethylated reaction or 29 cycles of 951C for 30s, 701C for
1min, and 721C for 1min for the methylated reaction, and one
cycle of 721C for 5min. DNAs from TE1 (oesophageal squamous
cell cancer cell line) and SW1417 (colon cancer cell line) were used
as positive controls of CDH13 amplification for unmethylated and
methylated alleles, respectively. The methylation status of SW1417
cells has already been examined previously (Toyooka et al, 2002).
Controls without DNA were performed for each set of PCR. In all,
10ml of each PCR product was directly loaded onto nondenaturing
6% polyacrylamide gels, stained with ethidium bromide, and
visualised under UV illumination. Each MSP was repeated at least
three times.
Reverse transcription–PCR (RT–PCR)
First-strand cDNA was generated from RNA as described
previously (Hibi et al, 1991). The PCR amplification consisted of
30 cycles (951C for 30s, 551C for 1min, and 721C for 1min) after
the initial denaturation step (951C for 2min). The primers used
were: CDH13-S (sense), 50-TTCAGCAGAAAGTGTTCCATAT, and
CDH13-AS (antisense), 50-GTGCATGGACGAACAGAGT. Primer
sequences were described previously (Sato et al, 1998). The
predicted size of PCR product was 208bp. The housekeeping gene,
b-actin, was used as an internal control to confirm the success of
the RT reaction.
Statistical analysis
The w
2 (Fisher’s exact) test and Student’s t-test were used to
examine the association between CDH13 promoter methylation
and clinicopathological features.
RESULTS
We first examined the methylation status of CDH13 in digestive
tract cancer cell lines using MSP. DNA from all three colorectal
cancer cell lines (SW1083, SW1222, and SW1417), two of three
gastric cancer cell lines (MKN1, NUGC3, and NUGC4), and none of
three oesophageal cancer cell lines (TE1, NUEC1, and NUEC2)
exhibited abnormal promoter methylation of CDH13 gene
(Figure 1). To confirm the status of CDH13 gene according to
the methylation pattern, we next examined CDH13 expression in
these cell lines using RT–PCR. Three colon and two gastric cancer
cell lines that demonstrated only methylation of the CDH13
promoter lacked CDH13 gene expression, while CDH13 was
expressed in all other cell lines with unmethylation of the
CDH13 promoter including one gastric and three oesophageal
cancer cell lines (Figure 1).
Subsequently, we examined whether aberrant methylation could
be detected in primary oesophageal and gastric cancers. Five of 37
oesophageal cancers (14%) and 23 of 66 gastric cancers (35%)
demonstrated abnormal methylation of the CDH13 promoter. In
our previous study, CDH13 methylation was detected in 27 of 84
primary colorectal cancers (32%) (data not shown). Representative
results of MSP analyses of CDH13 promoter are shown in Figure 2.
As a control, we screened for CDH13 methylation in the
corresponding normal epithelial DNA of 37 oesophageal and 66
gastric cancer patients. No methylation was found in the normal
DNA of this control group. As Figure 2 showed, all cases exhibited
unmethylation to a greater or lesser extent. Therefore, it might be
possible that the CDH13 gene expression has not been inhibited
completely in these cancers. It might also be possible that DNA
derived from inflammatory and interstitial cells among cancer cells
exhibited unmethylation because it is impossible to exclude these
cells completely from cancer cells obtained for this study.
After methylation analysis of all samples, clinicopathological
data were correlated with these results. Sex, age, extent of tumour,
clinical stage, lymph node metastasis, histology, and prognosis
were not significantly correlated with representations of abnormal
methylation in oesophageal or gastric cancers (Tables 1 and 2).
Compared with CDH13-unmethylated cancers, CDH13-methylated
cancers showed a trend towards preferentially invasive (P¼0.140)
and short time alive (P¼0.167) in oesophageal cancers. On the
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Figure 1 Representative MSP of CDH13 promoter in digestive tract cancer cell lines. The presence of a visible PCR product in lane U indicates the
presence of unmethylated genes; the presence of PCR product in lane M indicates the presence of methylated genes. All colon cancer cell lines (SW1083,
SW1222, and SW1417) and two gastric cancer cell lines (NUGC3 and NUGC4) that demonstrated only methylation of the CDH13 promoter lacked
CDH13 gene expression, while CDH13 was expressed in other cell lines with unmethylation of the CDH13 promoter.
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sother hand, abnormal methylation was found in gastric cancers of
patients at all clinical stages, suggesting that these cancers could be
methylated at an early stage.
DISCUSSION
Several tumour suppressor genes contain CpG islands in their
promoters, prompting many studies investigating the role of
methylation in silencing these genes. Many tumour suppressor
genes show evidence of methylation silencing, providing a new
potential pathway for the deactivation of tumour suppressor genes
(Jones and Laird, 1999).
CDH13, one among the cadherin family, would be a cell surface
glycoprotein responsible for cell adhesion. Recently, it was
reported that the promoter of E-cadherin, another of the cadherin
family, frequently underwent hypermethylation in human gastric
cancers (Tamura et al, 2000). Therefore, it is conceivable that
CDH13 was also inactivated in gastric cancers by promoter
methylation. In this study, CDH13 gene was methylated frequently
in gastric cancers, suggesting that the inactivation of this gene
plays an important role in this cancer while it does not do so in
oesophageal squamous cell cancers. Moreover, abnormal methyla-
tion was found in gastric cancers of patients at all clinical stages,
suggesting that these cancers could be methylated at an early stage.
These results suggested that CDH13 might play various roles
depending on the tissue types along the digestive tract.
As previously described, the methylation of CDH13 gene would
not be complete, suggesting that the CDH13 gene expression has
not been completely inhibited in primary cancers. Zheng et al
(2000) reported previously that a partial methylation pattern was
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Figure 2 Representative MSP of CDH13 promoter in primary oesophageal and gastric cancers. In each case, modified DNA from TE1 and SW1417 were
used as positive controls for unmethylated and methylated alleles, respectively. (A) Primary oesophageal cancers. Cases E27 and E28 exhibited methylation.
(B) Primary gastric cancers. Cases G31, G32, G33, G37, and G38 exhibited methylation.
Table 1 Clinicopathological features and CDH13 promoter methylation
in oesophageal cancer
CDH13 methylation
Clinicopathological
feature Variable
No. of
cases +   P-value
Sex Male 32 5 27 40.999
a
Female 5 0 5
Age 37 64.8710.0
b 62.377.8 0.356
c
Maximal size (cm) 37 5.471.3 4.671.9 0.528
c
Extent of tumour pmt
d 13 0 13 0.140
a
mt o 24 5 19
TNM stage 0–2 9 0 9 0.463
a
3, 4 28 5 23
Lymph node + 21 3 18 40.999
a
Metastasis 16 2 14
Prognosis Dead 22 4 18 0.629
a
Alive 15 1 14
Time alive (month)
e 22 7.873.8 19.7716.3 0.1672
Total 37 5 32
aFisher’s exact test.
bMean7s.d.
cStudent’s t-test.
dmt¼muscular tunic.
eDead people
only.
Table 2 Clinicopathological features and CDH13 promoter methylation
in gastric cancer
CDH13 methylation
Clinicopathological
feature Variable
No. of
cases +   P-value
Sex Male 49 17 32 0.964
a
Female 17 6 11
Age 66 62.7712.5
b 61.179.7 0.571
c
Extent of tumour pmt
d 20 6 14 0.586
a
mto 46 17 29
TNM stage 0–2 35 12 23 0.919
a
3, 4 31 11 20
Lymph node + 38 14 24 0.692
a
Metastasis 28 9 19
Prognosis Dead 32 11 21 40.999
a
Alive 34 12 22
Histology tub
e 27 10 17 0.756
a
por, muc, sig
f 39 13 26
Total 66 23 43
aw
2 test.
bMean7s.d.
cStudent’s t-test.
dmt, muscular tunic.
etub, tubular
adenocarcinoma.
fpor, poorly-differentiated adenocarcinoma; muc, mucinous adeno-
carcinoma; sig, signet-cell adenocarcinoma.
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sassociated with relatively low levels of p14ARF in colorectal cancer
cell lines. p14ARF mRNA was expressed at extremely low levels in
fully methylated cell lines, and p14ARF expression in the partial
methylated LoVo cell line was intermediate. Moreover, partial
methylation of p14ARF was the most common pattern observed in
primary colorectal cancers. Taken together, these findings suggest
that the level of CDH13 gene expression might also be controlled
by methylation in primary cancers.
Our results suggested that the aberrant methylation of CDH13
gene has been shown frequently in oesophageal and gastric
cancers. In addition, abnormal methylation was found in gastric
cancers of patients at all clinical stages, suggesting that these
cancers could be methylated at an early stage. Therefore, CDH13
methylation could be used as a tumour marker in clinical samples
such as serum and stool for the early detection of digestive tract
cancers (Hibi et al, 2001; Kanyama et al, 2003).
Recent studies have shown that it is possible to reverse
epigenetic changes and restore gene function to a cell. Treatment
with DNA methylation inhibitors can restore the activities of
CDH13 gene and decrease the growth rate of cancer cells. The
administration of drugs such as cytosine analogues might soon be
able to restore the function of these tumour suppressor genes and
slow the rate of cancer progression.
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